Low-dose oral clonidine. A simple and reliable growth hormone screening test for children

Area of Science:

• Pediatrics
• Endocrinology
• Pharmacology

Background:

• Short stature in children can be indicative of underlying growth hormone deficiency.
• Accurate and safe diagnostic tools are crucial for identifying growth hormone deficiency.
• Oral clonidine hydrochloride is being investigated for its potential in growth hormone stimulation testing.

Purpose of the Study:

• To evaluate the efficacy and side effects of low-dose oral clonidine hydrochloride in stimulating growth hormone (GH) release in healthy short children.
• To compare the effectiveness of two different low doses of clonidine hydrochloride (100 micrograms vs. 50 micrograms).
• To determine if clonidine hydrochloride is a safe and effective screening test for GH deficiency.

Main Methods:

• A total of 24 healthy short children were divided into two groups.
• Group A (10 children) received 100 micrograms of oral clonidine hydrochloride.
• Group B (14 children) received 50 micrograms of oral clonidine hydrochloride. Growth hormone levels were measured at 60 minutes post-administration.

Main Results:

• The mean growth hormone peak at 60 minutes was higher in Group A (14.5 +/- 6.3 mg/mL) compared to Group B (11.6 +/- 6.1 mg/mL).
• The failure rate (GH < 10 mg/mL) was significantly lower in Group A (10%) than in Group B (36%).
• Cortisol levels showed similar decreases in both groups, and blood pressure remained stable. Mild somnolence was the only notable side effect.

Conclusions:

• A single oral dose of clonidine hydrochloride at approximately 100 micrograms/sq m is an effective screening test for growth hormone deficiency in short children.
• This dosage demonstrates a lower failure rate and maintains safety with minimal side effects.
• Oral clonidine hydrochloride offers a safe and effective method for initial screening of growth hormone deficiency in pediatric populations.